Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Citizens BancShares Inc (FCNCA) vs GSK plc (GSK) Price & Performance

First Citizens BancShares IncTrade

Price performance (Past 24H)

Key statistics

First Citizens BancShares Inc vs GSK plc — how do they compare? First Citizens BancShares Inc trades at $2,278.08 (market cap $25.04B), while GSK plc trades at $50.37 (market cap $102.60B). The key difference: GSK plc is far larger — about 4.1× First Citizens BancShares Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

FCNCAGSK
Market Cap
$25.04B$102.60B
Sector
Sector/ThematicHealth
52-Week High
$2.27K$61.18
52-Week Low
$1.64K$38.96
Dividend Yield
0.37%3.57%
Enterprise Value
$123.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Citizens BancShares Inc

First Citizens BancShares (FCNCA) trades at $2,271.31, up 1.7% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by consistent revenue around $9.3B. Recent news highlights expansion in commercial lending and strategic leadership appointments, reinforcing growth initiatives.

Outlook remains positive due to earnings momentum and dividend stability, but risks include elevated uninsured deposits and net interest margin pressure. Analyst consensus is cautious with 82% hold ratings, suggesting limited near-term upside despite a $2,310 price target. Investors should weigh solid profitability against sector headwinds and valuation constraints.

GSK plc

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK